Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriparatide versus risedronate for glucocorticoid-induced osteoporosis in men
2006-006315-68Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2007
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of teriparatide and risedronate in glucocorticoid-induced osteoporosis (GIOP) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in lumbar spine volumetric trabecular bone mineral density. Started Feb 2007; status: completed.
02
Drugs
teriparatiderisedronate
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)
Beyond the preview
Go deeper on 2006-006315-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006315-68.